Palbociclib Stimulates CD8⁺ T Cell Response in Triple-Negative Breast Cancer via Regulating Phosphoglycerate Dehydrogenase

Researchers explored the effects of palbociclib (PALB) on triple-negative breast cancer. An in vivo assay was applied to determine the effects of PALB on breast cancer.